CRESCITA THERAPEUTICS INC (CTX.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CTX - CA2258471028 - Common Stock
0.45 CAD
0 (0%)
Taking everything into account, CTX scores 4 out of 10 in our fundamental rating. CTX was compared to 31 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CTX as it has an excellent financial health rating, but there are worries on the profitability. CTX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CTX had positive earnings in the past year.
In the past year CTX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CTX reported negative net income in multiple years.
In multiple years CTX reported negative operating cash flow during the last 5 years.
1.2 Ratios
CTX has a Return On Assets of 2.13%. This is in the better half of the industry: CTX outperforms 77.42% of its industry peers.
CTX has a Return On Equity of 2.81%. This is in the better half of the industry: CTX outperforms 77.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.13% | ||
| ROE | 2.81% | ||
| ROIC | N/A |
ROA(3y)-5.89%
ROA(5y)-4.27%
ROE(3y)-7.95%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CTX's Profit Margin of 2.07% is fine compared to the rest of the industry. CTX outperforms 70.97% of its industry peers.
With a decent Gross Margin value of 51.77%, CTX is doing good in the industry, outperforming 77.42% of the companies in the same industry.
In the last couple of years the Gross Margin of CTX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 2.07% | ||
| GM | 51.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.3%
GM growth 5Y-7.9%
2. Health
2.1 Basic Checks
CTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CTX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for CTX has been reduced compared to 5 years ago.
The debt/assets ratio for CTX has been reduced compared to a year ago.
2.2 Solvency
CTX has an Altman-Z score of -0.46. This is a bad value and indicates that CTX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.46, CTX is in line with its industry, outperforming 48.39% of the companies in the same industry.
CTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.35 | ||
| Altman-Z | -0.46 |
ROIC/WACCN/A
WACC8.02%
2.3 Liquidity
A Current Ratio of 3.12 indicates that CTX has no problem at all paying its short term obligations.
With a decent Current ratio value of 3.12, CTX is doing good in the industry, outperforming 74.19% of the companies in the same industry.
CTX has a Quick Ratio of 2.07. This indicates that CTX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 2.07, CTX belongs to the best of the industry, outperforming 80.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 117.32% over the past year.
Looking at the last year, CTX shows a very strong growth in Revenue. The Revenue has grown by 26.79%.
Measured over the past years, CTX shows a decrease in Revenue. The Revenue has been decreasing by -2.60% on average per year.
EPS 1Y (TTM)117.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%174.35%
Revenue 1Y (TTM)26.79%
Revenue growth 3Y5.3%
Revenue growth 5Y-2.6%
Sales Q2Q%50.06%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CTX is valuated rather expensively with a Price/Earnings ratio of 22.50.
Compared to the rest of the industry, the Price/Earnings ratio of CTX indicates a somewhat cheap valuation: CTX is cheaper than 74.19% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.28, CTX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.5 | ||
| Fwd PE | N/A |
4.2 Price Multiples
CTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CTX is cheaper than 100.00% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CTX is valued cheaper than 90.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.99 | ||
| EV/EBITDA | 1.01 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CTX (12/8/2025, 7:00:00 PM)
0.45
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.94%
Ins Owner ChangeN/A
Market Cap8.37M
Revenue(TTM)22.07M
Net Income(TTM)457.00K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.5 | ||
| Fwd PE | N/A | ||
| P/S | 0.38 | ||
| P/FCF | 5.99 | ||
| P/OCF | 4.12 | ||
| P/B | 0.52 | ||
| P/tB | 0.57 | ||
| EV/EBITDA | 1.01 |
EPS(TTM)0.02
EY4.44%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.08
FCFY16.69%
OCF(TTM)0.11
OCFY24.28%
SpS1.19
BVpS0.87
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.63
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.13% | ||
| ROE | 2.81% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 2.07% | ||
| GM | 51.77% | ||
| FCFM | 6.34% |
ROA(3y)-5.89%
ROA(5y)-4.27%
ROE(3y)-7.95%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.3%
GM growth 5Y-7.9%
F-Score8
Asset Turnover1.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.35 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 43.64% | ||
| Cap/Sales | 2.88% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 372.34% | ||
| Profit Quality | 305.91% | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.07 | ||
| Altman-Z | -0.46 |
F-Score8
WACC8.02%
ROIC/WACCN/A
Cap/Depr(3y)37.08%
Cap/Depr(5y)28.12%
Cap/Sales(3y)2.6%
Cap/Sales(5y)2.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)117.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%174.35%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)26.79%
Revenue growth 3Y5.3%
Revenue growth 5Y-2.6%
Sales Q2Q%50.06%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y72.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1647.5%
FCF growth 3YN/A
FCF growth 5Y-21.27%
OCF growth 1Y1594.17%
OCF growth 3YN/A
OCF growth 5Y-12.49%
CRESCITA THERAPEUTICS INC / CTX.CA FAQ
What is the ChartMill fundamental rating of CRESCITA THERAPEUTICS INC (CTX.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to CTX.CA.
Can you provide the valuation status for CRESCITA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 3 / 10 to CRESCITA THERAPEUTICS INC (CTX.CA). This can be considered as Overvalued.
How profitable is CRESCITA THERAPEUTICS INC (CTX.CA) stock?
CRESCITA THERAPEUTICS INC (CTX.CA) has a profitability rating of 3 / 10.